Health Partners Medicaid

Total Page:16

File Type:pdf, Size:1020Kb

Health Partners Medicaid Health Partners Plans Formulary Updated 12/6/2016 2017 Formulary Introduction (P&T) Committee supply must be accurately determined by the dispensing pharmacist to assure compliance with plan parameters. Health Partners Plans, Inc. is pleased to The actions of the Health Partners Plans Specific limits based on FDA guidelines, provide the 2017 Formulary. This formulary P&T Committee are communicated medication package inserts and accepted covers members under Health Partners through the Provider Newsletter to all standards of care may apply to medication Plans Medicaid plan. The drugs listed in the physicians and posted on our website. treatments under clinical review. Health Partners Plans Formulary are Pharmacy providers in the Health Prescription quantities cannot be altered intended to provide sufficient options to treat Partners Plans network will be notified unless approved by the physician, and must the majority of patients who require drug through correspondence from the Health be within the limits of the plan’s days supply. therapy in an ambulatory setting. Excluded Partners Plans pharmacy department. Prescribed medications or regimens that are from coverage are specific manufacturers non-formulary require prior authorization. who have not contracted with the rebate Product Selection Criteria program of the Federal government. The drugs listed in the Health Partners Immediate Need (5/15-day The Health Partners Plans P&T Committee Plans Formulary have been reviewed and Emergency Supply) approved by the Health Partners Plans will consider all FDA approved drugs for Pharmacy and Therapeutics Committee. inclusion in the formulary. The evaluation If a member presents at a pharmacy a These drug products have been selected to process includes a literature review; expert prescription which requires prior provide the most clinically appropriate opinion by respected medical professionals authorization, whether for a non-formulary and cost-effective medications for Health or through TEC (Technical Evaluation drug or otherwise, and if the prior Partners Plans members. There may be Center) may also be sought. Formal reviews authorization cannot be processed occasions when an unlisted drug is desired are prepared which typically address the immediately, Health Partners Plans will for medical management of a specific following information: allow the pharmacy to dispense an interim patient. In those instances, the unlisted 1. Safety supply of the prescription under the medication may be requested through Prior 2. Effectiveness following circumstances: Authorization/ Medical Exception. 3. Comparison studies 4. Approved indications If the recipient is in immediate need of the 5. Adverse effects medication in the professional judgment of Preface 6. Contraindications the pharmacist and if the prescription is for a 7. Pharmacokinetics new medication (one that the recipient has The Health Partners Plans Formulary is 8. Patient compliance considerations not taken before or that is taken for an acute organized by sections, which refer to either 9. Medical outcome and condition), Health Partners Plans will allow a drug/ pharmacologic class or disease pharmacoeconomic studies the pharmacy to dispense a 5-day supply of state. Each section contains a list of drugs When a new drug is considered for the medication to afford the recipient or selected to be on this formulary. Prescribing formulary inclusion an attempt will be made pharmacy the opportunity to initiate the a drug product that is available generically is to examine the drug relative to similar drugs request for prior authorization. encouraged when appropriate. currently on formulary. In addition, entire If the prescription is for an ongoing Prescriptions for generically available non- therapeutic classes are periodically medication (one that is continuously prescription (OTC) drugs deemed medically reviewed. This review process may result in prescribed for the treatment of an illness or necessary by the plan are eligible for deletion of a drug(s) in a particular condition that is chronic in nature in which coverage. Generally, OTC medications are therapeutic class in an effort to continually there has not been a break in treatment for less costly than prescription alternatives and promote the most clinically useful and cost- greater than 34 Days), Health Partners their use can contribute to cost-effective effective agents. Plans will allow the pharmacy to dispense a therapy. The over-the-counter (OTC) 15-day supply of the medication products listed in the formulary are covered Plan Limits automatically, unless Health Partners Plans with a prescription. mailed to the member, with a copy to the A maximum of 30-day supply of medication prescriber, an advanced written notice of the is eligible for coverage. The prescriber is reduction or termination of the medication at urged to prescribe in amounts that adhere to least 10 days prior to the end of the period for which the medication was previously Pharmacy and Therapeutics accepted standards of care. The days authorized. i Health Partners Plans Formulary Updated 12/6/2016 Health Partners Plans will respond to the strength and dosage form as the brand specific products. These medications may request for prior authorization within 24 name counterpart. require Prior Authorization for the following hours from when the request was received. The FDA has given the generic an “A” rating reasons: If the prior authorization is denied, the compared to the branded counterpart Non-formulary medications, or benefit recipient is entitled to appeal the decision indicating bioequivalence and has exceptions required by medical through several avenues. The 5-day or 15- determined the generic is therapeutically necessity day requirement does not apply when the equivalent to the referenced brand. The All brand name medications when pharmacist determines that taking the ratings of generic drugs are available by there is an A-rated generic equivalent medication, either alone or along with other referring to the FDA reference Approved available medication that the recipient may be taking, Drug Products with Therapeutic Equivalence Medications and/or treatments under would jeopardize the health and safety of Evaluations (Orange Book). clinical investigation the recipient. When the above two criteria are met, a Medications used for non-FDA generic can be substituted with the full approved indications expectation that the substituted product will Formulary Product Prescription costs that exceed $1000 produce the same clinical effect and safety Descriptions per claim profile as the brand name product. Prescriptions that exceed set plan State laws or regulation may indicate the limits (days supply, quantity, cost) This formulary lists all specific strengths and ability to practice generic substitution for Prescriptions processed by non- dosage forms that are covered. When a selected products or categories of drugs. network pharmacies strength or dosage form is specified, There are now many brand name products New-to-market products only the product identified will be that are repackaged or distributed under a High end oral and self administered covered. Other strengths/ dosage forms generic label. These generic versions injectable medications of the referenced product are not should always be considered therapeutically covered. equivalent and substitutable for the source Medications with Health Partners For specific questions please contact the branded product irrespective of rating. Plans P&T Committee approved treatment guidelines Health Partners Plans Pharmacy department at 215-991-4300. Drugs Efficacy Study To request a prior authorization the Implementation (DESI) Drugs physician or a member of his/her staff Generic Substitution should contact Health Partners Plans Health Partners Plans does not reimburse either by fax at (866) 240-3712, or phone Generic substitution is the process by which for DESI drugs. DESI drugs are those drugs at (215) 991-4300. All non-emergency a generic equivalent is dispensed rather first marketed between 1938 and 1962 requests can be faxed 24 hours per day; than the brand name product. The which were approved as safe, but not calls should be placed from 9:00 A.M. to appropriate use of generic drugs is one required to show effectiveness for FDA 5:00 P.M., Monday through Friday. method of providing cost conscious drug product approval. The DESI program In the event of an immediate need after therapy. Health Partners Plans will not subsequently made a determination of fully business hours, the call should be made to cover any drugs by companies that do not effective for most of these products and they Health Partners Plans Member Services at participate in the Federal Rebate Program remain in the marketplace. A few DESI (800) 553-0784. The call will be evaluated or are DESI drugs. Generic drugs must be products remain classified as less than fully and routed to a pharmacist-on-call. prescribed and dispensed when an A-rated effective while awaiting final administrative The physician may use the Health Partners generic drug is available. Brand necessary disposition. Also classified as DESI are Plans Prior Authorization/Medical Exception prescriptions for drugs with A-rated generics many products listed as identical, similar, or form or a letter of request, but must include require prior authorization. related to actual DESI products. the following information for quick and The MAC list sets a ceiling price for the Examples
Recommended publications
  • 30 Day Change Notice Effective Date
    30 Day Change Notice Effective Date: January 1st, 2021 NEW PREFERRED DRUGS THERAPEUTIC CLASS NO PA REQUIRED PREFERRED Central Nervous System (CNS) Agents: Anticonvulsants Clobazam (Generic of Onfi) Central Nervous System (CNS) Agents: Multiple Aubagio EndocrineSclerosis Agents: Osteoporosis-Bone Ossification Forteo Enhancers Gastrointestinal Agents: Anti-Emetics Bonjesta Genitourinary Agents: Benign Prostatic Hyperplasia Alfuzosin (Generic of Uroxatral) Dutasteride (Generic of Avodart) Genitourinary Agents: Electrolyte Depleter Agents Sevelamer (Generic of Renagel and Renvela) Infectious Disease Agents: Antibiotics-Macrolides Eryped Infectious Disease Agents: Antivirals-HIV Atazanavir Sulfate Oral Powder (Generic of Reyataz) Tivicay PD Infectious Disease Agents: Antibiotics-Tetracyclines Vibramycin Suspension (no PA Required for age 12 or under) Ophthalmic Agents: Antibiotics and Antibiotic -Steroid Neomycin/Polymyxin/Bacitracin/Hydrocortisone Ointment Combination Drops and Ointments Ophthalmic Agents: Glaucoma Agents Dorzolamide/Timolol (Generic of Cosopt PF) NEW CLINICAL PA REQUIRED “PREFERRED” DRUGS THERAPEUTIC CLASS CLINICAL PA REQUIRED PREFERRED Blood Formation, Coagulation, and Thrombosis Agents: Corifact Hemophilia Factors Immunomodulator Agents for Systemic Inflammatory Taltz Disease Immunomodulator Agents for Systemic Inflammatory Xeljanz 5mg Disease NEW STEP THERAPY REQUIRED “PREFERRED” THERAPEUTIC CLASS STEP THERAPY REQUIRED “PREFERRED” Central nervous System (CNS) Agents: Anti-Migraine, Aimovig Prophylaxis Treatment Ajovy
    [Show full text]
  • Active Pharmaceutical Ingredients
    Active Pharmaceutical Ingredients Catalog HPD-5E ® CREATING A HEALTHY WORLDTM Active Pharmaceutical Ingredients (APIs) Available for International Markets Human Pharmaceutical Department www.Pharmapex.net Catalog HPD-5E *Not all products referred to on this site are available in all countries and our products are subject to different regulatory requirements depending on the country of use. Consequently, certain sections of this site may be indicated as being intended only for users in specic countries. Some of the products may also be marketed under different trade names. You should not construe anything on this site as a promotion or solicitation for any product or for the use of any product that is not authorized by the laws and regulations of your country of residence. For inquiries about the availability of any specic product in your country, you may simply contact us at [email protected]. **Products currently covered by valid US Patents may be offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk. ©2016, Pharmapex USA, A member of Apex Group of Companies, All Rights Reserved. Toll-Free: 1.844.PHARMAPEX Fax: + 1.619.881.0035 ACTIVE PHARMACEUTICAL [email protected] CREATING A HEALTHY WORLD™ www.Pharmapex.net INGREDIENTS About Pharmapex’s Human Pharmaceuticals Department: Pharmapex’s Human Pharmaceuticals Department (HPD) is a leading source for high-quality Active Pharmaceutical Ingredients (APIs) and Finished Pharmaceutical Products (FPPs) in various markets across the globe. With an extensive product portfolio, our consortium of companies is dedicated to addressing and solving the most important medical needs of our time, including oncology (e.g., multiple myeloma and prostate cancer), neuroscience (e.g., schizophrenia, dementia and pain), infectious disease (e.g., HIV/AIDS, Hepatitis C and tuberculosis), and cardiovascular and metabolic diseases (e.g., diabetes).
    [Show full text]
  • Staying on Schedule: How to Take Each HIV Medicine
    11 1 11 12 1 11 1 11 12 1 10 2 10 2 10 2 10 2 9 33 9 33 9 33 9 33 8 4 8 4 8 4 8 4 7 6 5 7 6 5 7 6 5 7 6 5 Staying on Schedule How to take each HIV medicine HIV medicines are a key part of your HIV treatment. They can reduce the amount of HIV in your blood to very low levels and help restore your immune system health and your overall health. When you start taking HIV medicines, it is a big commitment. You have to take HIV medicines on time, exactly as they are prescribed, for them to work properly. What this booklet does: • Shows a picture of each HIV medicine. • Lists the amount of the drug in each dose (the amount you take may vary). • Tells you when to take the medicine and whether or not to eat food with it. • Gives general tips for taking each HIV medicine. An HIV medicine schedule is different for everyone. Your doctor or health care provider will work closely with you to decide which medicines to take and how much to1 take. Ask questions before you start taking a medicine When you pick up a new prescription or a refill of an HIV medicine at the drugstore, read the directions carefully. If you don’t understand anything about taking the medicine, ask the pharmacist to explain. Make sure the medicines look the same as the ones you are taking. Check to see if the instructions for taking them are the same instructions given by your doctor or health care provider.
    [Show full text]
  • INTEGRIS Formulary July 2017
    INTEGRIS Formulary July 2017 Foreword FORMULARY EXCLUDED THERAPEUTIC DRUG This document represents the efforts of the MedImpact Healthcare Systems THERAPEUTIC DRUGS CLASS Pharmacy and Therapeutics (P & T) and Formulary Committees to provide ALTERNATIVES physicians and pharmacists with a method to evaluate the safety, efficacy and cost- clindamycin/tretinoin, ACNE AGENTS, effectiveness of commercially available drug products. A structured approach to the VELTIN drug selection process is essential in ensuring continuing patient access to rational ZIANA TOPICAL drug therapies. The ultimate goal of the MedPerform Formulary is to provide a morphine sulfate ER process and framework to support the dynamic evolution of this document to guide tablets, oxycodone ANALGESICS, KADIAN prescribing decisions that reflect the most current clinical consensus associated ER, NUCYNTA, NARCOTICS with drug therapy decisions. NUCYNTA ER ANALGESICS, This is accomplished through the auspices of the MedImpact P & T and Formulary BELBUCA BUTRANS PATCH Committees. These committees meet quarterly and more often as warranted to NARCOTICS ensure clinical relevancy of the Formulary. To accommodate changes to this ABSTRAL, document, updates are made accessible as necessary. FENTORA, fentanyl citrate ANALGESICS, LAZANDA, lozenge NARCOTICS As you use this Formulary, you are encouraged to review the information and ONSOLIS, provide your input and comments to the MedImpact P & T and Formulary SUBSYS Committees. immediate-release GRALISE ANTICONVULSANTS The MedImpact P & T
    [Show full text]
  • Printed Formulary Catalog Basic
    Scripps Health Formulary July 2016 Foreword Pharmacy and Therapeutics Committee. MedImpact approves such multi- This document represents the efforts of the MedImpact Healthcare Systems source drugs for addition to the MAC list based on the following criteria: Pharmacy and Therapeutics (P & T) and Formulary Committees to provide physicians A multi-source drug product manufactured by at least one (1) nationally and pharmacists with a method to evaluate the safety, efficacy and cost-effectiveness marketed company. of commercially available drug products. A structured approach to the drug selection At least one (1) of the generic manufacturer’s products must have an “A” process is essential in ensuring continuing patient access to rational drug therapies. rating or the generic product has been determined to be unassociated with The ultimate goal of the Portfolio Formulary is to provide a process and framework to efficacy, safety or bioequivalency concerns by the MedImpact P & T support the dynamic evolution of this document to guide prescribing decisions that Committee. reflect the most current clinical consensus associated with drug therapy decisions. Drug product will be approved for generic substitution by the MedImpact P & T Committee. This is accomplished through the auspices of the MedImpact P & T and Formulary Committees. These committees meet quarterly and more often as warranted to ensure This list is reviewed and updated periodically based on the clinical literature and clinical relevancy of the Formulary. To accommodate changes to this document, pharmacokinetic characteristics of currently available versions of these drug updates are made accessible as necessary. products. As you use this Formulary, you are encouraged to review the information and provide If a member or physician requests a brand name product in lieu of an approved your input and comments to the MedImpact P & T and Formulary Committees.
    [Show full text]
  • Preferred Drug List
    Comprehensive PREFERRED DRUG LIST MHS Indiana Effective 04/01/2017 PAGE 1 LAST UPDATED 04/2017 Pharmacy Program MHS Health Plan (MHS) is committed to providing appropriate, high-quality, and cost- effective drug therapy to all MHS members. MHS works with providers and pharmacists to ensure that medications used to treat a variety of conditions and diseases are covered. MHS covers prescription medications and certain over-the-counter (OTC) medications when ordered by an Indiana Medicaid enrolled MHS practitioner. The pharmacy program does not cover all medications. Some medications require prior authorization (PA) or have limitations on age, dosage, and maximum quantities. For the most current information about the MHS Pharmacy Program you may call Member Services at (877) 647-4848 (TTY/TTD (800) 743-3333) or visit the MHS website www.mhsindiana.com. Preferred Drug List The MHS Preferred Drug List (PDL) is the list of covered drugs. The PDL applies to drugs that members can receive at retail pharmacies. The MHS PDL is continually evaluated by the MHS Pharmacy and Therapeutics (P&T) Committee to promote the appropriate and cost-effective use of medications. The Committee is composed of the MHS Medical Director, MHS Pharmacy Director, and several Indiana physicians, pharmacists, and specialists. Pharmacy Benefit Manager Envolve Pharmacy Solutions (EPS) is our Pharmacy Benefit Manager. MHS works with EPS to process all pharmacy claims for prescribed drugs. Some drugs on the MHS PDL require PA, and EPS is responsible for administering this process. Specialty Drugs Certain medications are only covered when supplied by MHS’ specialty pharmacy provider. AcariaHealth is our specialty pharmacy provider.
    [Show full text]
  • Glaxosmithkline Plc Annual Report for the Year Ended 31St December 2000
    GlaxoSmithKline 01 GlaxoSmithKline plc Annual Report for the year ended 31st December 2000 Contents Report of the Directors 02 Financial summary 03 Joint statement by the Chairman and the Chief Executive Officer 05 Description of business 29 Corporate governance 37 Remuneration report 47 Operating and financial review and prospects 69 Financial statements 70 Directors’ statements of responsibility 71 Report by the auditors 72 Consolidated statement of profit and loss 72 Consolidated statement of total recognised gains and losses 74 Consolidated statement of cash flow 76 Consolidated balance sheet 76 Reconciliation of movements in equity shareholders’ funds 77 Company balance sheet 78 Notes to the financial statements 136 Group companies 142 Principal financial statements in US$ 144 Financial record 153 Investor information 154 Shareholder return 156 Taxation information for shareholders 157 Shareholder information 158 Share capital 160 Cross reference to Form 20-F 162 Glossary of terms The Annual Report was approved by the Board 163 Index of Directors on 22nd March 2001 and published on 12th April 2001. Contact details 02 GlaxoSmithKline Financial summary 2000 1999 Increase Business performance £m £m CER % £ % Sales 18,079 16,164 9 12 Trading profit 5,026 4,378 12 15 Profit before taxation 5,327 4,708 11 13 Earnings/Net income 3,697 3,222 13 15 Earnings per Ordinary Share 61.0p 52.7p 14 16 Total results Profit before taxation 6,029 4,236 Earnings/Net income 4,154 2,859 Earnings per Ordinary Share 68.5p 46.7p Business performance: results exclude merger items and restructuring costs; 1999 sales and trading profit exclude the Healthcare Services businesses which were disposed of in 1999.
    [Show full text]
  • Malta Medicines List April 08
    Defined Daily Doses Pharmacological Dispensing Active Ingredients Trade Name Dosage strength Dosage form ATC Code Comments (WHO) Classification Class Glucobay 50 50mg Alpha Glucosidase Inhibitor - Blood Acarbose Tablet 300mg A10BF01 PoM Glucose Lowering Glucobay 100 100mg Medicine Rantudil® Forte 60mg Capsule hard Anti-inflammatory and Acemetacine 0.12g anti rheumatic, non M01AB11 PoM steroidal Rantudil® Retard 90mg Slow release capsule Carbonic Anhydrase Inhibitor - Acetazolamide Diamox 250mg Tablet 750mg S01EC01 PoM Antiglaucoma Preparation Parasympatho- Powder and solvent for solution for mimetic - Acetylcholine Chloride Miovisin® 10mg/ml Refer to PIL S01EB09 PoM eye irrigation Antiglaucoma Preparation Acetylcysteine 200mg/ml Concentrate for solution for Acetylcysteine 200mg/ml Refer to PIL Antidote PoM Injection injection V03AB23 Zovirax™ Suspension 200mg/5ml Oral suspension Aciclovir Medovir 200 200mg Tablet Virucid 200 Zovirax® 200mg Dispersible film-coated tablets 4g Antiviral J05AB01 PoM Zovirax® 800mg Aciclovir Medovir 800 800mg Tablet Aciclovir Virucid 800 Virucid 400 400mg Tablet Aciclovir Merck 250mg Powder for solution for inj Immunovir® Zovirax® Cream PoM PoM Numark Cold Sore Cream 5% w/w (5g/100g)Cream Refer to PIL Antiviral D06BB03 Vitasorb Cold Sore OTC Cream Medovir PoM Neotigason® 10mg Acitretin Capsule 35mg Retinoid - Antipsoriatic D05BB02 PoM Neotigason® 25mg Acrivastine Benadryl® Allergy Relief 8mg Capsule 24mg Antihistamine R06AX18 OTC Carbomix 81.3%w/w Granules for oral suspension Antidiarrhoeal and Activated Charcoal
    [Show full text]
  • Index B Alphabetical List of Pharmaceutical Product Names
    INDEX B ALPHABETICAL LIST OF PHARMACEUTICAL PRODUCT NAMES PRODUCT NAME Page PRODUCT NAME Page 292 97 ACYCLOVIR 17 3TC (EDS) 14 ACYCLOVIR 17 5-AMINOSALICYLIC ACID (MESALAMINE) 170 " 18 ABACAVIR SO4 13 ADALAT XL 57 ABACAVIR SO4/LAMIVUDINE 13 ADALIMUMAB 220 ABACAVIR SO4/LAMIVUDINE/ZIDOVUDINE 13 ADAPALENE 206 ABATACEPT 220 ADCIRCA (EDS) 89 ABILIFY (EDS) 123 ADEFOVIR DIPIVOXIL 18 ACARBOSE 187 ADHESIVE WIPES (EDS) 239 ACCEL PIOGLITAZONE (EDS) 190 ADVAGRAF (EDS) 231 ACCEL TOPIRAMATE 112 ADVAIR (EDS) 33 ACCEL-CITALOPRAM 114 ADVAIR DISKUS (EDS) 33 ACCOLATE (EDS) 232 AGGRENOX (EDS) 87 ACCU-CHEK 1 MINI (EDS) 238 AGRYLIN 221 ACCU-CHEK 2 MINI (EDS) 238 AIROMIR 32 ACCU-CHEK ADVANTAGE 142 ALCOHOL PREP 234 ACCU-CHEK AVIVA 142 ALCOHOL SWAB 234 ACCU-CHEK COMPACT 142 ALDACTAZIDE-25 82 ACCU-CHEK FASTCLIX MOBILE 234 ALDACTAZIDE-50 82 ACCU-CHEK LINKASSIST (EDS) 239 ALDACTONE 148 ACCU-CHEK MOBILE 142 ALDARA (EDS) 209 ACCU-CHEK MULTICLIX 234 ALENDRONATE (EDS) 220 ACCU-CHEK RAPID D (EDS) 236 ALENDRONATE SODIUM 220 " 237 ALENDRONATE SODIUM (EDS) 220 " 238 ALENDRONATE SODIUM/VITAMIN D3 ACCU-CHEK SPIRIT (EDS) 236 (CHOLECALCIFEROL) 220 ACCU-CHEK TENDER 1 (EDS) 238 ALERTEC (EDS) 133 " 239 ALESSE 181 ACCU-CHEK TENDER 2 (EDS) 238 ALFACALCIDOL 217 " 239 ALFUZOSIN 220 ACCU-CHEK ULTRAFLEX 1 (EDS) 237 ALGLUCOSIDASE ALFA 221 " 238 ALLOPURINOL 221 ACCU-CHEK ULTRAFLEX 2 (EDS) 237 ALMOTRIPTAN MALATE 33 " 238 ALOMIDE 158 ACCUPRIL 79 ALPHAGAN 157 ACCURETIC 80 ALPHAGAN P 157 ACCUTANE 209 ALPRAZOLAM 134 ACCUTREND 142 ALPRAZOLAM 134 ACEBUTOLOL 48 ALTACE 80 ACEBUTOLOL HCL 48 " 81
    [Show full text]
  • Pharmacokinetics of Ophthalmic Corticosteroids
    British Journal ofOphthalmology 1992; 76: 681-684 681 MINI REVIEW Br J Ophthalmol: first published as 10.1136/bjo.76.11.681 on 1 November 1992. Downloaded from Pharmacokinetics of ophthalmic corticosteroids Corticosteroids have been used by ophthalmologists with an identical vehicle, the aqueous humour concentrations of increasing frequency over the past 30 years, with the these steroids are almost identical.'9 None the less it is concomitant development of a diverse range of drop, essential when considering such empirical data, to recall that ointment, subconjunctival, and oral preparations. Though the systemic anti-inflammatory effect of both betamethasone the clinical benefits and side effects of such corticosteroid and dexamethasone is five to seven times that of predniso- preparations have been well documented, their basic lone.39"' The local anti-inflammatory potency of ocular pharmacokinetics in the human eye have yet to be fully steroids has yet to be fully investigated and whilst early work established. Indeed most of our pharmacokinetic knowledge suggested that prednisolone acetate 1% had the greatest anti- of these drugs has been elucidated by extrapolation of data inflammatory effect in experimental keratitis,'7 later studies obtained from rabbit experiments.1-26 These results can be demonstrated that fluorometholone acetate in a 1% formu- significantly disparate from human data because of the lation was equally efficacious in the same model.26 However, thinner rabbit cornea, lower rabbit blink rate, effect of prednisolone
    [Show full text]
  • Teva Pharmaceutical Industries Ltd
    m n a d v s g o PRODUCT v1 2015 CATALOGUE h p b e q f i t w c l r z www.tapi.com PRODUCT CATALOGUE v1 2015 US CEP EU Japan Korea DMF DMF DMF DMF ABIRATERONE a ACYCLOVIR x x x AFATINIB ALCLOMETASONE DIPROPIONATE x x ALENDRONATE SODIUM x x x ALLOPURINOL x x x x AMCINONIDE x x x AMITRIPTYLINE HCL x x x x x AMLODIPINE BESYLATE x x x ANASTROZOLE x x x ANIDULAFUNGIN APIXABAN APREMILAST ARIPIPRAZOLE x x ARIPIPRAZOLE LAUROXIL ATORVASTATIN CALCIUM* x x x x ATOSIBAN ACETATE ATRACURIUM BESYLATE x x x AZACITIDINE x x AZITHROMYCIN x x x x AZTREONAM x BECLOMETHASONE DIPROPIONATE x x x x b BETAMETHASONE ACETATE x x x BETAMETHASONE BASE x x x BETAMETHASONE DIPROPIONATE x x x x BETAMETHASONE VALERATE x x x x BICALUTAMIDE x x BIMATOPROST x x BIVALIRUDIN x x BLEOMYCIN SULFATE x x BORTEZOMIB x x x * TAPI can provide several different polymorphs or processes of this product. To obtain complete DMF files of a specific product's polymorph or process, please contact your account manager. For the most updated product list please go to "Products" at www.tapi.com Additional DMFs or Tech Files are available upon request All subject to the disclaimer on page 15 PRODUCT CATALOGUE v1 2015 US CEP EU Japan Korea DMF DMF DMF DMF BROMOCRIPTINE MESYLATE x x b BUDESONIDE x x x x BUPRENORPHINE BASE x x BUPRENORPHINE HCL x x x BUTORPHANOL TARTRATE x x CABAZITAXEL x CABERGOLINE x x x x c CALCIPOTRIENE (CALCIPOTRIOL)* x x x CALCITRIOL x x x CANDESARTAN CILEXETIL x CAPECITABINE x x CARBIDOPA x x x x CARBOPLATIN x x x x CARFILZOMIB CARVEDILOL BASE x x x x x CARVEDILOL PHOSPHATE x CASPOFUNGIN ACETATE x x CERITINIB CHLORMADINONE ACETATE x x CICLOSPORIN x x x x x CILOSTAZOL x x x x CINACALCET HCL x x CISATRACURIUM BESYLATE x x CISPLATIN x x x CLARITHROMYCIN x x x x x CLOBETASOL PROPIONATE x x x x x CLONAZEPAM x CLOPIDOGREL BISULFATE x x x x CYPROTERONE ACETATE x x d DABIGATRAN ETEXILATE x DARIFENACIN HBR x x * TAPI can provide several different polymorphs or processes of this product.
    [Show full text]
  • Preferred Drug List (PDL)
    Preferred Drug List (PDL) New Jersey – MLTSS Effective Date: 7/15/2021 © 2021 United HealthCare Services, Inc. All Rights Reserved. UnitedHealthcare Community Plan does not treat members differently because of sex, age, race, color, disability or national origin. If you think you were treated unfairly because of your sex, age, race, color, disability or national origin, you can send a complaint to: Civil Rights Coordinator UnitedHealthcare Civil Rights Grievance P.O. Box 30608 Salt Lake City, UTAH 84130 [email protected] You must send the complaint within 60 days of when you found out about it. A decision will be sent to you within 30 days. If you disagree with the decision, you have 15 days to ask us to look at it again. If you need help with your complaint, please call the toll-free member phone number listed on your health plan member ID card, TTY 711, 24 hours a day, 7 days a week. You can also file a complaint with the U.S. Dept. of Health and Human Services. Online: https://ocrportal.hhs.gov/ocr/portal/lobby.jsf Complaint forms are available at http://www.hhs.gov/ocr/office/file/index.html Phone: Toll-free 1-800-368-1019, 1-800-537-7697 (TDD) Mail: U.S. Dept. of Health and Human Services 200 Independence Avenue SW Room 509F, HHH Building Washington, D.C. 20201 If you need help with your complaint, please call the toll-free member phone number listed on your member ID card. We provide free services to help you communicate with us, such as letters in other languages or large print.
    [Show full text]